Document Type
Article
Publication Date
12-18-2024
Identifier
DOI: 10.1186/s12969-024-01048-1
Abstract
BACKGROUND: Most patients with a pediatric rheumatic disease are at increased risk of influenza due to immunosuppressive medication use. Despite initial quality improvement efforts, our influenza vaccination rate plateaued at 72%, which prompted a survey of patients and families to assess provider vaccine recommendations, influenza knowledge, and barriers to influenza vaccination.
METHODS: Patients on immunosuppressive medication or their parent were eligible to complete a survey between July 2019 and January 2020. Survey questions assessed demographics, rheumatology diagnosis, immunosuppressive medication(s), influenza vaccination recommendation, patient/parent influenza knowledge, and barriers to influenza vaccination. Influenza vaccination rates for immunosuppressed patients were acquired each influenza season from 2015-2020 and tracked on a control chart.
RESULTS: Of the 226 completed surveys, 145 (64.2%) were completed by parents and 81 (35.8%) by patients. The majority (85%) reported the influenza vaccine was recommended. The most common reasons for not receiving the influenza vaccine included: worry about disease flare (25.6%), concern the vaccine will cause influenza (25.6%), and lack of vaccine effectiveness (20.5%). Parents (40.9%) were more worried about disease flare compared to patients (17%; p = 0.024). Most respondents were able to correctly answer fever, cough and/or congestion as the most common symptoms of influenza; however, 23% answered gastrointestinal symptoms and 10.2% joint swelling. Most respondents (95.1%) were aware that immunosuppressive medication increases risk of infection. The average weekly influenza vaccination rate for the 2019-2020 flu season was 85.5%, which increased from 72.0% the previous year. Parents with higher education status were more likely to have their child receive the influenza vaccine compared to parents with less education.
CONCLUSIONS: This survey indicates that respondents understand the potential severity of influenza and the increased risk of infection due to immunosuppressive medication use; however, many inaccurately identified the most common symptoms of influenza and also reported misconceptions of influenza vaccine risks. The barriers identified in this survey will help drive future improvement efforts to increase influenza vaccination rates in this high-risk population.
Journal Title
Pediatr Rheumatol Online J
Volume
22
Issue
1
First Page
104
Last Page
104
MeSH Keywords
Humans; Influenza, Human; Immunocompromised Host; Influenza Vaccines; Male; Female; Health Knowledge, Attitudes, Practice; Child; Rheumatic Diseases; Immunosuppressive Agents; Vaccination; Adolescent; Parents; Surveys and Questionnaires
Keywords
Influenza; Pediatric rheumatology; Vaccination
Recommended Citation
Harris JG, Favier L, Jones JT, et al. Influenza knowledge and barriers to vaccination in immunosuppressed patients in the pediatric rheumatology clinic. Pediatr Rheumatol Online J. 2024;22(1):104. Published 2024 Dec 18. doi:10.1186/s12969-024-01048-1
Included in
Influenza Humans Commons, Influenza Virus Vaccines Commons, Pediatrics Commons, Rheumatology Commons
Comments
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Publisher's Link: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-024-01048-1